• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Malaysia continues national journey to battle hepatitis C with global partners

Home > Press releases

Malaysia continues national journey to battle hepatitis C with global partners

Man and woman looking at a phone
Kuala Lumpur — 27 Jul 2021
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
  • English
    • English
    • Bahasa Malaysia
    • 中文
    • தமிழ்
    • ไทย
  • Following the publication of World Health Organization (WHO) recommendations on hepatitis C self-testing, Malaysia will become one of the global forerunners in using this innovative new technology in one of the first-ever hepatitis C self-testing impact studies.
  • This study will provide critical data on impact and help guide effective roll-out and scale-up of hepatitis C self-testing services globally.

FIND, the global alliance for diagnostics, is partnering with the Ministry of Health (MoH) Malaysia, the Malaysian AIDS Council (MAC), World Health Organization (WHO), and the Drugs for Neglected Diseases initiative (DNDi) to launch a hepatitis C virus self-testing impact study in Malaysia.

Shared ahead of World Hepatitis Day 2021, the impact study announcement was made during the webinar Hepatitis C can’t wait, Malaysia isn’t waiting – following WHO advisory of the new hepatitis C virus self-testing recommendations shared at the International AIDS Society (IAS) Conference.

Earlier in June, Malaysia announced the conditional approval for ravidasvir to treat hepatitis C. Being part of this global hepatitis c self-testing impact study solidifies Malaysia’s commitment to eliminate hepatitis C by 2030. It is estimated that there are more than 400,000 people living with hepatitis C in Malaysia, but only 1% of them have been treated. Since the end of 2019, Malaysia has adopted decentralized care for hepatitis C by enabling primary healthcare facilities to test and treat the disease.

Datuk Dr Muhammad Radzi Abu Hassan, National Head of Gastroenterology and Hepatology, Ministry of Health shared, ‘Through this impact study, we will be able to understand if self-testing can increase testing uptake among people currently not reached by facility-based testing, which can expand equity and access in hepatitis C care.‘

Set to be conducted in partnership with a community-based organization – the Malaysian AIDS Council (MAC) – the impact study will build on existing work done for HIV self-testing, via the online platform JOM TEST, and is aimed to test those who may be missed by the usual facility-based testing.

‘Testing continues to play a crucial part of hepatitis C treatment, enabling those tested to receive proper care,’ said Datuk Dr Christopher Lee, President of Malaysian AIDS Council. ‘We are proud to assist in this impact study to understand the impact of providing self-testing as an additional approach for diagnosis to help stop anyone from falling through the cracks, denying their access to treatment.‘

Dr Noor Hisham Abdullah, Director General, Ministry of Health, Malaysia said, ‘Malaysia is proud to be at the cutting edge of innovations to tackle hepatitis C, and all this is possible because where there is a will, there is always a way. We are happy to be granted opportunities to work together with partners such as FIND, DNDi, MAC and WHO to reach our goal of hepatitis C elimination by 2030.‘

Dr Meg Doherty, Director, Global HIV, Hepatitis, STI Programmes, WHO said, ‘We congratulate Malaysia’s swift action in responding to the WHO global launch of the first HCV self-testing guidelines, announced at the International AIDS Society Conference 2021 on 18 July 2021. This has implications for scaling-up testing coverage among key and vulnerable populations as well as among groups with a higher burden on hepatitis C virus infections and can facilitate national action towards elimination of the disease by 2030.‘

Dr Bill Rodriguez, CEO of FIND said, ‘Hepatitis C continues to be a public health concern for most countries in the world. By implementing this self-testing study so soon after the new guidelines have been released, Malaysia is once again leading the way in assessing strategies that can defeat this disease, providing information that will be critical not only for Malaysia but also for many other countries. It is a privilege to be part of this partnership that is so committed to disease elimination.‘

‘HCV is unique because we can design effective public health strategies of elimination with affordable treatments,’ said Jean-Michel Piedagnel, Director of DNDi South-East Asia. ‘After the announcement of the conditional approval for ravidasvir, this study continues to put Malaysia on the map as a warrior against hepatitis C. We are proud to be part of a team that continues to innovate on screening strategies to make elimination possible.‘

World Hepatitis Day takes place every year on 28 July with a purpose to raise awareness of the disease. Hepatitis C is a silent disease, as the huge majority of those infected are not aware of their status, show no symptoms of the disease, and therefore do not seek treatment.

About FIND

FIND, the global alliance for diagnostics, seeks to ensure equitable access to reliable diagnosis around the world. We connect countries and communities, funders, decision-makers, healthcare providers and developers to spur diagnostic innovation and make testing an integral part of sustainable, resilient health systems. We are working to save 1 million lives through accessible, quality diagnosis, and save US$1 billion in healthcare costs to patients and health systems. We are co-convener of the Access to COVID-19 Tools (ACT) Accelerator diagnostics pillar, and a WHO Collaborating Centre for Laboratory Strengthening and Diagnostic Technology Evaluation. For more information, please visit www.finddx.org

About DNDi

A not-for-profit research and development organization, DNDi works to deliver new treatments for neglected patients, those living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, and hepatitis C. DNDi is also coordinating the ANTICOV clinical trial to find treatments for mild-to-moderate COVID-19 in Africa. Since its inception in 2003, DNDi has delivered nine new treatments to date, including new drug combinations for kala-azar, two fixed-dose antimalarials, and DNDi’s first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness. dndi.org

About WHO

The World Health Organization provides global leadership in public health within the United Nations system. Founded in 1948, WHO works with 194 Member States across six regions, to promote health, keep the world safe and serve the vulnerable. Our goal for 2019-2023 is to ensure that a billion more people have universal health coverage, to protect a billion more people from health emergencies, and provide a further billion people with better health and well-being. who.int/

About Malaysian AIDS Council

Malaysian AIDS Council (Malay: Majlis AIDS Malaysia, abbrev: MAC) was established in 1992 under the Ministry of Health (MOH) with a mission to represent, mobilise and strengthen non-governmental organisations and communities who were working with HIV/AIDS issues. MAC works with its partner organisations in a diverse range of activities from advocating and policy reforms; developing awareness and communication materials; creating public awareness campaigns; conducting and organising workshops and seminars; rolling out prevention and education programmes; providing care and support services and psychological counselling. www.mac.org.my/

Media contacts

FIND 

Sarah-Jane Loveday 
Director of Communications 
M: +41 79 431 62 44 
media@finddx.org 

ROOTS PR (Kuala Lumpur) 

Sara Sabri  
sara.sabri@rootsasia.com 
+60 14 3385945 

DNDi 

Frédéric Ojardias (Geneva) 
fojardias@dndi.org  
+41 79 431 62 16 

Molly Jagpal (Kuala Lumpur) 
mjagpal@dndi.org 
+60 12 546 8362 

Ilan Moss (New York) 
imoss@dndi.org 
+1 646 266 5216 

Photo credit: Abang Amirrul Hadi – DNDi

Registration & access Hepatitis C Asia Malaysia

Read, watch, share

Loading...
Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

Lab activities
News
20 Feb 2023

First in-person Dengue Alliance meeting brings together experts from dengue-endemic countries to develop treatments for a growing viral threat

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo